Home > Boards > US OTC > Basic Materials >

Bioxytran Inc. (BIXT)

Add BIXT Price Alert      Hide Sticky   Hide Intro
Moderator: Chess Master
Search This Board: 
Last Post: 11/26/2019 10:29:03 AM - Followers: 19 - Board type: Free - Posts Today: 0

Bioxytran, Inc. is a biopharmaceutical company whose mission is to develop anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.
The company focuses on the development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The Company’s lead product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. It will be tested as a potent resuscitative agent to treat Ischemic brain strokes, also known as Cardiac Cerebrovascular Accidents (CVA). In addition, our drug candidate, BXT-252, will be tested as a regenerative agent in a variety of wound healing applications.
Bioxytran, Inc. is working to develop new molecules that address unmet medical needs. Bioxytran, Inc.’s drug candidates have a large market potential as anti-necrotic drugs for multiple disease indications that result from hypoxia.

Management Team

David Platt, PhD/CEO and Chariman of the Board

Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials. Prior to BioXyTran Inc. Dr. Platt founded Boston Therapeutics Inc. in 2010 (OTC: BTHE). Between 2001 and 2009, Dr. Platt became a founder of Pro-Pharmaceuticals, Inc. (OTC: PRWP and AMEX: PRW, now NASDAQ: GALT), and served as its chief executive officer and board chairman. In 1995 Dr. Platt founded International Gene Group (NASDAQ: IGGI, GLGS now LPJC); he continued to serve the firm through 2000.

Ola Soderquist, CPA, CMA, CM&AA/ CFO

Mr. Soderquist has more than 30 years of senior international entrepreneurial management experience within technology companies. He has served in CFO and other managerial capacities in multiple industry sectors and companies, such as Industrivarden (OMX:INDU), Electrolux (OMX:ELUX), Ericsson (NASDAQ:ERIC),  Swedish Match (OMX:SWMA) and SKF AB (OMX:SKF), and most recently in Belden (NYSE: BDC) and Traction (OMX:TRAC). Ola is a multi-lingual senior finance professional poised to work globally and cross-functionally, particularly with complex projects involving business integration, systems implementation, continuous improvement, and process excellence. Ola’s managerial experience portfolio includes; Start-ups, Private, Public, Venture Capital and Private Equity ownership. He obtained a BS and an MS in Accounting from Stockholm School of Economics and an MBA from Babson College – Franklin W. Olin Graduate School of Business.

Juan Carlos Talavera / Scientific Advisory Board

Dr. Lopez-Talavera has over 20 years of experience in the biopharma industry, with extensive expertise in liver and gastrointestinal diseases. Most recently, Dr. Lopez-Talavera was Senior Vice President, Head of Medical Affairs and member of the Executive Team at Intercept Pharmaceuticals. Previously he held positions at AbbVie as Head of Medical Affairs, Global Research and Development, Bristol Myers Squibb, as Vice President and Global Development Lead, and Roche Laboratories as Senior Medical Director. Before moving into the industry, Dr. Lopez-Talavera was an Assistant Professor with the Divisions of Gastroenterology and Hepatology, and Endocrinology and Pathology at the University of Pittsburgh Medical Center, Associate Professor of Medicine with the Universidad Autónoma de Barcelona and Attending Physician of the Liver Unit at the Hospital General Universitari Vall D’Hebron in Barcelona.

Investment Thesis

? Experienced management: BioXyTran, Inc.’s management team has a successful track record in the biotech and pharmaceutical arena, with decades of collective experience.
? Focus on novel therapeutic opportunities: To date, only a few drugs have been approved for ischemic stroke, wound healing and TBI . There is currently no effective way to treat necrosis or hypoxia. Oxygen Therapy Inc. is positioned to become a major player in this field of unmet medical needs.
? Balanced profile: Our two leading products for humans position Oxygen Therapy Inc. as a leader in two large and growing hypoxia-treatment markets.
? Drugs are differentiated formulations: Our lead drug product candidates are well-differentiated and designed to treat complications of hypoxia.
? Intellectual property and market protection: The Company owns a key patent and is developing a robust intellectual property portfolio of patent applications and trademarks. 

                                MUST SEE VIDEO - START HERE

Lead Molecule


BioXyTran Inc.’s drug BXT-25 is designed to oxygenate ischemic (reduced blood flow) regions in the brain that suffered from hypoxia during a brain stroke. To minimize irreversible damage to the brain, it may be administered prior during and after current available treatments such as rt-PA to dissolve the clot and to have a positive confounding effect by keeping the brain oxygenated. The glycoprotein drug BXT-25 is a modified hemoglobin structure, bound to a proprietary co-polymer chemical structure. This new chemical structure offers significant improvement because there is no treatment to deliver oxygen prior to removing the blockage (clot) by rTPA or surgery. BXT-25’s co-polymer proprietary chemical structure acts as the main carrier of oxygen, instead of the Red Blood Cell which are blocked by the clot. BXT-25 construct substantially reduces methemoglobin formation and nitric oxide scavenging that may contribute to a variety of disorders—such as renal failure, vasoconstriction, hypertension, myocardial infarction, and related toxicity issues.

Furthermore, BXT-25’s small size, roughly 1/5,000th that of a red blood cell, enables it to perfuse constricted, ischemic capillaries that are inaccessible to red blood cells due to clots or other obstructions. The new molecule is stable in solution for 3 years at 250°C. and can be freeze-dried (lyophilized) for an even longer shelf life.


52wk Range: 0.06 - 1.65
Avg Vol (3m): 3,142                  5/28/19
Market Cap: 110,634,775       5/24/19
Share Statistics
Avg Vol (3 month): 3,142
Shares Outstanding: 85.10 M     5/3/19
Float: 7.65 M      4/24/19


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BIXT News: Current Report Filing (8-k) 01/15/2020 04:01:11 PM
BIXT News: Statement of Changes in Beneficial Ownership (4) 01/10/2020 02:40:23 PM
BIXT News: Current Report Filing (8-k) 01/06/2020 04:27:12 PM
BIXT News: Current Report Filing (8-k) 12/11/2019 07:53:53 AM
BIXT News: Current Report Filing (8-k) 11/25/2019 05:09:27 PM
#502   NEW ARTICLE - BIXT mention at the end Chess Master 11/26/19 10:29:03 AM
#501   This stuff is amazing. So in my research BugStocks_com 10/31/19 09:59:29 AM
#500   These guys with their technology can go after Chess Master 10/31/19 09:40:30 AM
#499   Is BXT25 only going after STROKE? What other BugStocks_com 10/30/19 09:53:57 AM
#498   MORE NEWS - looks like a great conference Chess Master 10/30/19 09:50:13 AM
#497   LINKAGE TO NOBEL PRIZE - https://www.globenewswire.com/news-release/2019/ Chess Master 10/16/19 04:18:49 PM
#496   LINKAGE TO NOBEL PRIZE - https://www.globenewswire.com/news-release/2019/ Chess Master 10/16/19 04:18:41 PM
#495   Chart still looks good. Love to see Chess Master 09/29/19 08:56:25 PM
#494   Up nice highstakes 09/16/19 10:48:54 AM
#493   Report out highstakes 09/13/19 06:29:20 PM
#492   Is it kicking again ? highstakes 08/27/19 06:17:32 PM
#491   Will this hold ? highstakes 08/21/19 10:40:39 AM
#490   this is a great company. Chess Master 08/16/19 06:30:41 PM
#489   I like $BIXT .... great potential!! Zardiw 08/02/19 09:29:29 AM
#488   Great volume. Todays the day to double. highstakes 07/22/19 10:08:07 AM
#487   1.45 up highstakes 07/18/19 01:11:45 PM
#486   Ask at 135 highstakes 07/17/19 10:46:41 AM
#485   Ask moving 158 to 135 Early highstakes 07/17/19 07:37:23 AM
#484   Hmmm highstakes 07/16/19 06:10:13 PM
#483   Up 20 Volume? highstakes 07/16/19 09:53:18 AM
#482   Well its moving. Ask 1.00 highstakes 07/16/19 09:48:18 AM
#481   Whats going on here ? Second push highstakes 07/16/19 09:01:19 AM
#480   Seems like stroke is the focus but this Chess Master 06/11/19 11:55:37 AM
#479   I agree, GREAT ARTICLE, the potential here is HUGE! BugStocks_com 06/10/19 12:26:28 PM
#478   Great Article Just Out in BIXT! Chess Master 06/10/19 12:08:37 PM
#477   $ BIXT NEWS ~ BIOXYTRAN’S MDX VIEWER DEMONSTRATES EARLY jedijazz 06/06/19 09:28:33 AM
#476   Looks like a seller knocked it down. Chess Master 06/05/19 10:16:02 PM
#475   Nice High print $1.75 and had a $2.00 Chess Master 06/04/19 02:11:10 AM
#474   From the timing and the big bid in Chess Master 06/03/19 03:43:22 PM
#473   $ BIXT $1.75 +38.89% Market liking last weeks news jedijazz 06/03/19 02:50:36 PM
#472   STROKE BLOG POSTING - One of the top Chess Master 06/02/19 05:15:26 PM
#471   Good info on the increasing buy interest in ProfitScout 05/31/19 09:41:25 AM
#470   $BIXT Bioxytran Inc. Overall Average: mtrendspotter 05/31/19 09:28:39 AM
#469   The new presentation on the BIXT website is ProfitScout 05/30/19 02:41:51 PM
#468   $BIXT Bioxytran Inc. Announces Availability of Updated Investor StockHighAlert- 05/30/19 01:55:51 PM
#467   Did you see the presentation? Very ambitious Chess Master 05/30/19 12:10:01 AM
#466   Bioxytran Inc. Announces Availability of Updated Investor Presentation ProfitScout 05/29/19 01:43:52 PM
#465   $BIXT Overall Average: mtrendspotter 05/29/19 11:30:09 AM
#464   Juan Carlos is a real stud. I Chess Master 05/28/19 08:38:00 PM
#463   Its crazy not to use this TMS in Chess Master 05/28/19 08:18:30 PM
#462   Its really thinly traded but the chart is Chess Master 05/28/19 08:10:53 PM
#461   This new vital sign is quite an advancement. Chess Master 05/28/19 08:06:59 PM
#460   The very productive collaboration between Bioxytran and MDX ProfitScout 05/28/19 02:15:52 PM
#459   $BIXT Using Paradigm Changing Vital Sign that Can mtrendspotter 05/28/19 09:06:56 AM
#458   $BIXT The device measures 4 parameters and mtrendspotter 05/24/19 09:30:45 AM
#457   We are seeing very significant advancements being reported ProfitScout 05/23/19 10:58:09 AM
#456   $BIXT Bioxytran Using Paradigm Changing Vital Sign that StockHighAlert- 05/21/19 03:26:56 PM
#455   BIXT is starting to gain higher awareness and ProfitScout 05/21/19 12:26:28 PM
#454   Bioxytran, Inc. ( BIXT ) 1.15 +0.15 (15.00%) jedijazz 05/21/19 11:51:37 AM
#453   $ BIXT Bioxytran Inc In Today's News & Barchart jedijazz 05/20/19 01:10:49 PM